[go: up one dir, main page]

WO2017168014A8 - Markersequenzen für rheumatoide arthritis - Google Patents

Markersequenzen für rheumatoide arthritis Download PDF

Info

Publication number
WO2017168014A8
WO2017168014A8 PCT/EP2017/057896 EP2017057896W WO2017168014A8 WO 2017168014 A8 WO2017168014 A8 WO 2017168014A8 EP 2017057896 W EP2017057896 W EP 2017057896W WO 2017168014 A8 WO2017168014 A8 WO 2017168014A8
Authority
WO
WIPO (PCT)
Prior art keywords
marker sequences
rheumatoid arthritis
novel
diagnostic
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/057896
Other languages
English (en)
French (fr)
Other versions
WO2017168014A1 (de
Inventor
Angelika LÜKING
Petra Budde
Peter Schulz-Knappe
Dieter ZUCHT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to US16/090,620 priority Critical patent/US20190120834A1/en
Priority to EP17719812.4A priority patent/EP3436828A1/de
Publication of WO2017168014A1 publication Critical patent/WO2017168014A1/de
Anticipated expiration legal-status Critical
Publication of WO2017168014A8 publication Critical patent/WO2017168014A8/de
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein neues Verfahren zur Identifizierung von Markersequenzen für Rheumatoide Arthritis, die mit Hilfe des Verfahrens gefundenen neuen Markersequenzen und deren diagnostische Verwendung. Ferner betrifft die Erfindung diagnostische Vorrichtungen enthaltend solche Markersequenzen für Rheumatoide Arthritis, insbesondere einen Proteinbiochip oder Beads (Kügelchen) und deren Verwendung.
PCT/EP2017/057896 2016-04-02 2017-04-03 Markersequenzen für rheumatoide arthritis Ceased WO2017168014A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/090,620 US20190120834A1 (en) 2016-04-02 2017-04-03 Marker sequences for rheumatoid arthritis
EP17719812.4A EP3436828A1 (de) 2016-04-02 2017-04-03 Markersequenzen für rheumatoide arthritis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16163611 2016-04-02
EP16163611.3 2016-04-02
EP16170028.1 2016-05-16
EP16170028 2016-05-17

Publications (2)

Publication Number Publication Date
WO2017168014A1 WO2017168014A1 (de) 2017-10-05
WO2017168014A8 true WO2017168014A8 (de) 2018-10-04

Family

ID=58638826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/057896 Ceased WO2017168014A1 (de) 2016-04-02 2017-04-03 Markersequenzen für rheumatoide arthritis

Country Status (3)

Country Link
US (1) US20190120834A1 (de)
EP (1) EP3436828A1 (de)
WO (1) WO2017168014A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411979B2 (ja) * 2019-07-19 2024-01-12 公立大学法人福島県立医科大学 内部標準遺伝子
US12064466B2 (en) * 2021-04-27 2024-08-20 Academia Sinica Methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
ATE283930T1 (de) 1998-04-30 2004-12-15 Max Planck Gesellschaft NEUE METHODE ZUR SELEKTION VON KLONEN EINER EXPRESSIONSBIBLIOTHEK MITTELS ßREARRAYINGß
DE69921982T2 (de) 1998-04-30 2005-12-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
US20070254300A1 (en) 1999-12-02 2007-11-01 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
JP2005278479A (ja) 2004-03-29 2005-10-13 Hidetoshi Inoko 関節リウマチ検査用マーカー遺伝子
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
GB0701728D0 (en) * 2007-01-30 2007-03-07 Imp Innovations Ltd Assays and therapy
US20110098188A1 (en) * 2007-05-14 2011-04-28 The Scripps Research Institute Blood biomarkers for psychosis
DE102007041656A1 (de) 2007-09-03 2009-05-07 Protagen Ag Markersequenzen für rheumatoide Arthritis und deren Verwendung
CN101842705A (zh) 2007-09-03 2010-09-22 普罗塔根股份公司 用于类风湿性关节炎的标记序列及其应用
EP2286233A2 (de) 2008-05-14 2011-02-23 INSERM (Institut National de la Santé et de la Recherche Medicale) Verfahren und kits zur diagnose von rheumatoider arthritis
WO2010037856A2 (en) * 2008-10-03 2010-04-08 Stichting Katholieke Universiteit, Universitair Medisch Centrum St. Radboud DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS
EP2441848A1 (de) * 2010-10-12 2012-04-18 Protagen AG Markersequenzen für systemischer Lupus Erythematodes und deren Verwendung
EP2644704A1 (de) * 2012-03-27 2013-10-02 Protagen AG Markersequenzen für Rheumatoide Arthritis

Also Published As

Publication number Publication date
US20190120834A1 (en) 2019-04-25
EP3436828A1 (de) 2019-02-06
WO2017168014A1 (de) 2017-10-05

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
SG11202003923PA (en) Methods and kits using nucleic acid encoding and/or label
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
SG11202003924YA (en) Kits for analysis using nucleic acid encoding and/or label
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
EP4257690A3 (de) Hybride crispr-dns/rns-polynukleotide und verfahren zur verwendung
WO2015188839A3 (en) Detection and isolation of specific cells by binding of lebeled molecules
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
PH12017501815A1 (en) Humanized anti-c1s antibodies and methods of use thereof
GB2567360A (en) Methods for optical micropatterning of hydrogels and uses thereof
EP4556571A3 (de) Redoxmarkierte oligonukleotidsonden und deren verwendung
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
WO2017168014A8 (de) Markersequenzen für rheumatoide arthritis
WO2015153949A3 (en) Compositions and methods for identifying ehrlichia species
HK40124058A (en) Kits for analysis using nucleic acid encoding and/or label
DE102014013644A8 (de) Lyase und für die Lyase kodierende DNA, die DNA enthaltende Vektoren, sowie Verfahren zur asymmetrischen Synthese von (S)-Phenylacetylcarbinol
HK40017965A (en) Methods for identifying and using small rna predictors
HK40001683A (en) Systems and methods for performing biological assays
PL410572A1 (pl) Aptamer DNA rozpoznający ludzkie białko PCNA oraz jego zastosowanie

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017719812

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17719812

Country of ref document: EP

Kind code of ref document: A1